The DOI matches its Crossref record; 73 of the 79 references it cites were found in a registry or an index.
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
Open accessAbstract
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused more than 1 million deaths in the first 6 months of the pandemic and huge economic and social upheaval internationally. An efficacious vaccine is essential to prevent further morbidity and mortality. Although some countries might deploy COVID-19 vaccines on the strength of safety and immunogenicity data alone, the goal of vaccine development is to gain direct evidence of vaccine efficacy in protecting humans against SARS-CoV-2 infection and COVID-19 so that manufacture of efficacious vaccines can be selectively upscaled. A candidate vaccine against SARS-CoV-2 might act against infection, disease, or transmission, and a vaccine capable of reducing any of these elements could contribute to disease control. However, the most important efficacy endpoint, protection against severe disease and death, is difficult to assess in phase 3 clinical trials. In this Review, we explore the challenges in assessing the efficacy of candidate SARS-CoV-2 vaccines, discuss the caveats needed to interpret reported efficacy endpoints, and provide insight into answering the seemingly simple question, "Does this COVID-19 vaccine work?"
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the long-term risks and benefits of a SARS-CoV-2 vaccine will take a long time to fully evaluate in adults33 while the public health needs of a vaccine are pressing.”
From SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges (2021) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,300
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Prevalence of Asymptomatic SARS-CoV-2 Infection
Oran, D. P., & Topol, E. J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3012 · Cited by 2,348
The Architecture of SARS-CoV-2 Transcriptome
Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J. W., Kim, V. N., & Chang, H. (2020) · Cell · doi:10.1016/j.cell.2020.04.011 · Cited by 2,123
Research works printed but not linked: 1
- Yu, 2020, DNA vaccine protection against SARS-CoV-2 in rhesus macaques, Science, 369, 806, 10.1126/science.abc6284 · DOI · Paper page
Cited by
Sorted by citations
Items 201–300 of 633
Golshani, M., & Hrdý, J. (2022) · Vaccines · doi:10.3390/vaccines10020279 · Cited by 15
Inverse Association between Omega-3 Index and Severity of COVID-19: A Case–Control Study
Ramírez-Santana, M., Barra, R. Z., González, M. Ñ., Müller, J., Vásquez, J., Ravera, F., Lago, G., Cañón, E., Castañeda, D., & Pradenas, M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19116445 · Cited by 11
Lin, X., Zhang, M., Chen, Y., Xue, J.-J., Chen, H.-D., Tung, T., & Zhu, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.770933 · Cited by 15
Jahangir, M. A. (2021) · International Journal of Pharmaceutics & Pharmacology · doi:10.31531/2581-3080.1000153 · Cited by 13
Distinguishing Pneumonia and COVID-19: Utilizing Computer Vision to Mimic Clinician Efficacy
Saha, I., Gourisaria, M. K., & Harshvardhan, G. M. (2021) · International Conference on Artificial Intelligence and Smart Energy (ICAIS) · doi:10.1109/icais50930.2021.9395961 · Cited by 14
Vaccination roll-out: a time to develop and maintain trust in science and health care
Muldoon, O. T., Bradshaw, D., Jay, S., Kinsella, E. L., Maher, P. J., Murphy, R. P., Taaffe, C., & O’Donnell, P. (2021) · British Journal of General Practice · doi:10.3399/bjgp21x717629 · Cited by 14
Cocchio, S., Zabeo, F., Facchin, G., Piva, N., Furlan, P., Nicoletti, M., Saïa, M., Tonon, M., Mongillo, M., Russo, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10010107 · Cited by 14
Kaabi, N. A., Oulhaj, A., Hosani, F. I. A., Mazrouei, S. K. A., Najim, O., Hussein, S. E., Abdalla, J. S., Fasihuddin, M. S., Hassan, A., ElGhazali, G. E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-04244-1 · Cited by 14
Vaccination as an alternative to non-drug interventions to prevent local resurgence of COVID-19
Pan, J., Zhu, W., Tian, J., Liu, Z., Xu, A., Yao, Y., & Wang, W. (2022) · Infectious Diseases of Poverty · doi:10.1186/s40249-022-00960-6 · Cited by 14
Marra, A. R., Miraglia, J. L., Malheiros, D. T., Guozhang, Y., Teich, V., Victor, E. D. S., Pinho, J. R. R., Cypriano, A. S., Vieira, L. W., Polonio, M., et al. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.50 · Cited by 14
Xie, D., Choi, H. K., Dalbeth, N., Wallace, Z. S., Sparks, J. A., Lu, N., Zeng, C., Li, X., Wei, J., Lei, G., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42339 · Cited by 14
COVID-19: The Pseudo-Environment and the Need for a Paradigm Change
Stein, R. A., Ometa, O., & Broker, T. R. (2021) · GERMS · doi:10.18683/germs.2021.1283 · Cited by 16
An Outbreak of COVID-19 among mRNA-Vaccinated Nursing Home Residents
Faggiano, F., Rossi, M. A., Cena, T., Milano, F., Barale, A., Ristagno, Q., & Silano, V. (2021) · Vaccines · doi:10.3390/vaccines9080859 · Cited by 12
Jose, S., Dhandapani, M., Cyriac, M., & Joseph, J. (2021) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2022.63.2.1952 · Cited by 12
Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines
Hromić‐Jahjefendić, A., Lundstrom, K. H., Adilović, M., Aljabali, A. A. A., Tambuwala, M. M., Serrano‐Aroca, Á., & Uversky, V. N. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103508 · Cited by 14
Jearanaiwitayakul, T., Limthongkul, J., Kaofai, C., Apichirapokey, S., Chawengkirttikul, R., Sapsutthipas, S., Sunintaboon, P., & Ubol, S. (2022) · Biomedicines · doi:10.3390/biomedicines10051142 · Cited by 13
Zhu, W., Zhu, Y., Wen, Z., Zheng, B., Xu, A., Yao, Y., & Wang, W. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07816-2 · Cited by 13
Letafati, A., Eyvazzadeh, N., Gharehkhani, A., Khorshidian, A., Chalabiani, S., Soufiani, E. K., Khakpoor, N., Shamsodini, B., Beheshti, T., Olyaei, R. T. B., et al. (2023) · Biologicals · doi:10.1016/j.biologicals.2023.101668 · Cited by 12
Evaluating the efficiency of public policy measures against COVID-19
Güner, R., Hasanoğlu, İ., & Aktaş, F. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2106-301 · Cited by 13
Past to Present, Epidemiology of SARS-CoV-2 Infection and Ways of Treatment: A Review
Uluçay, O., Altunkülah, E., & Alkaşi, Ü. (2022) · Kafkas Journal of Medical Sciences · doi:10.5505/kjms.2022.90757 · Cited by 12
Chen, C., Xie, D., & Xiao, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1100617 · Cited by 12
Understanding COVID-19 vaccine hesitancy in Malaysia: Public perception, knowledge, and acceptance
Mohamed, N. A., Solehan, H. M., Rani, M. D. M., Ithnin, M., & Arujanan, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284973 · Cited by 12
Global Mapping of Indigenous Resilience Facing the Challenge of the COVID-19 Pandemic
Lugo-Morín, D. R. (2021) · Challenges · doi:10.3390/challe12010015 · Cited by 26
Was Sleep a Problem for the Elderly During COVID-19?
Parveen, S., George, S. M., & Chand, S. (2021) · Sleep and Vigilance · doi:10.1007/s41782-021-00164-2 · Cited by 12
Chico-Sánchez, P., Gras-Valentí, P., Algado-Sellés, N., Jiménez-Sepúlveda, N. J., Vanaclocha, H., Peiró, S., Burgos, J. S., Berenguer, A., Navarro, D., & Sánchez–Payá, J. (2022) · Preventive Medicine · doi:10.1016/j.ypmed.2022.107237 · Cited by 12
Núñez, L., Ramírez-Santana, M., Rubilar, P. A., Vial, C., Apablaza, M., González, C., Said, M., Olivares, K., Cortés, J., Hormazábal, J., et al. (2023) · Viruses · doi:10.3390/v15010201 · Cited by 13
Klimek, L., Pfaar, O., Hamelmann, E. H., Kleine‐Tebbe, J., Taube, C., Wagenmann, M., Werfel, T., Brehler, R., Novak, N., Mülleneisen, N. K., et al. (2021) · Allergologie select · doi:10.5414/alx02245e · Cited by 12
Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
Sa-nguanmoo, N., Namdee, K., Khongkow, M., Ruktanonchai, U., Zhao, Y., & Liang, X. (2021) · Nano Research · doi:10.1007/s12274-021-3832-y · Cited by 12
Chen, S., Liu, T., Li, X., Luo, Y., Xiao, L., Zhang, L., Wen, R., & Lin, Y. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s335803 · Cited by 12
Elbadawi, M. H., Altayib, L. S., Birier, A. B., Ali, L. E., Hasabo, E. A., Esmaeel, M. A. M., Elmahi, O. K. O., & Group of collaborators (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2132082 · Cited by 12
Zhang, H., Liu, X., Liu, Q., Mei, H., Wang, Y., Cui, G., & Zhao, S. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.01.064 · Cited by 11
Relationship between blood clots and COVID-19 vaccines: A literature review
Atyabi, S. M. H., Rommasi, F., Ramezani, M. H., Ezabadi, M. F. G., Arani, M. A., Sadeghi, M. H., Ahmed, M. M., Rajabi, A., Dehghan, N., Sohrabi, A., et al. (2022) · Open Life Sciences · doi:10.1515/biol-2022-0035 · Cited by 12
Predictors of receiving COVID-19 vaccine among adult population in Iran: an observational study
Soleimanpour, H., Sarbazi, E., Esmaeili, E. D., Mehri, A., Fam, S. G., Nikbakht, H., Saadati, M., Sedighi, S., Vali, M., & Azizi, H. (2023) · BMC Public Health · doi:10.1186/s12889-023-15409-0 · Cited by 11
A systematic review on impact of SARS-CoV-2 infection
Gowripriya, T., Radhakrishnan, Y., Ramamurthi, S., Bhaskar, J. P., & Balamurugan, K. (2023) · Microbiological Research · doi:10.1016/j.micres.2023.127364 · Cited by 12
Maher, S., assaly, N. M. E., Aly, D. M., Atta, S. A., Fteah, A. M., Badawi, H., Zahran, M. Y., & Kamel, M. M. (2024) · Virology Journal · doi:10.1186/s12985-024-02546-0 · Cited by 11
Christodoulakis, A., Bouloukaki, I., Aravantinou-Karlatou, A., Zografakis‐Sfakianakis, M., & Tsiligianni, I. (2024) · Vaccines · doi:10.3390/vaccines12121411 · Cited by 13
Bhopal, S., Olabi, B., & Bhopal, R. S. (2020) · Public Health · doi:10.1016/j.puhe.2021.01.011 · Cited by 16
αVβ6 Integrin: An Intriguing Target for COVID‐19 and Related Diseases
Bugatti, K. (2021) · ChemBioChem · doi:10.1002/cbic.202100209 · Cited by 10
Silva, V. O., Yamashiro, R., Ahagon, C. M., de Campos, I. B., de Oliveira, I. P., de Oliveira, E. L., Lopes, G. I. S. L., Matsuda, E. M., Castejón, M. J., & Brígido, L. F. D. M. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27396 · Cited by 11
Macchia, A., Ferrante, D., Bouzas, M. B., Angeleri, P., Biscayart, C., Geffner, J. R., Mammana, L., Zapiola, I., López, E. L., de Gentile, A. S., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100196 · Cited by 11
The Attitude of Parents Toward Their Children Receiving the COVID-19 Vaccine
Alghamdi, S. (2022) · Children · doi:10.3390/children9091308 · Cited by 11
Evaluation of SARS-CoV-2-Specific T-Cell Activation with a Rapid On-Chip IGRA
Ning, B., Chandra, S., Rosen, J., Multala, E., Argrave, M., Pierson, L. M., Trinh, I. V., Simone, B. K., Escarra, M. D., Drury, S. S., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c09018 · Cited by 11
Polypharmacology of ambroxol in the treatment of COVID-19
Wang, Z., Yang, M., Chen, X., Xiao, R., Dong, Y. Q., Chu, M., Song, G., & Wang, Y. (2023) · Bioscience Reports · doi:10.1042/bsr20221927 · Cited by 11
Walmsley, S. L., Szadkowski, L., Wouters, B. G., Clarke, R., Colwill, K., Rochon, P. A., Brudno, M., Ravindran, R., Raboud, J., McGeer, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106506 · Cited by 12
Lu, W., Zeng, S., Yao, Y., Luo, Y., & Ruan, T. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1338208 · Cited by 11
Luo, M., Sun, J., Gong, Z., & Wang, Z. (2021) · BioScience Trends · doi:10.5582/bst.2021.01218 · Cited by 11
SARS-CoV-2 vaccines: Clinical endpoints and psychological perspectives: A literature review
Malik, J. A., Aroosa, M., Ahmed, S., Shinde, M., Alghamdi, S., Almansour, K., Hagbani, T. A., Alanazi, M. S., & Anwar, S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.03.017 · Cited by 9
Alter, G., Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-200342/v1 · Cited by 9
Chen, K., Zhang, L., Fang, Z., Li, J., Li, C., Song, W., Huang, Z., Chen, R., Zhang, Y., & Li, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294288 · Cited by 10
Understanding COVID-19 vaccination program among Indonesian public
Widjaja, G., Zahari, M., Hastuti, P., Nugraha, A. R., & Kusumawaty, I. (2021) · International Journal of Health Sciences · doi:10.53730/ijhs.v5n3.1429 · Cited by 10
In-silico screening of naturally derived phytochemicals against SARS-CoV Main protease
Mostafa, I., Mohamed, N. H., Mohamed, B., Almeer, R., Abulmeaty, M. M. A., BUNGAU, S. G., El-Shazly, A. M., & Yahya, G. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-17642-9 · Cited by 10
A Case of Hemophagocytic Lymphohistiocytosis following Second Dose of COVID-19 Vaccination
Park, H. W., Min, G. J., Kim, T. Y., & Cho, S. (2022) · Acta Haematologica · doi:10.1159/000526980 · Cited by 10
Vaccination efficacy in patients with chronic lymphocytic leukemia
Wang, K. Y., Shah, P., Skavla, B., Fayyaz, F., Chi, J., & Rhodes, J. M. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2133538 · Cited by 10
Success of nano-vaccines against COVID-19: a transformation in nanomedicine
Sarangi, M. K., Padhi, S. K., Rath, G., Nanda, S. S., & Yi, D. K. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2148659 · Cited by 11
Effect of religious fatalism and concern about new variants on the acceptance of COVID-19 vaccines
Mamani-Benito, O. J., Farfán-Solís, R., Huayta-Meza, M. E., Tito-Betancur, M., Morales-García, W. C., & Tarqui, E. E. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1071543 · Cited by 10
Recurring SARS-CoV-2 variants: an update on post-pandemic, co-infections and immune response
Verma, A., Manojkumar, A., Dhasmana, A., Tripathi, M. K., Jaggi, M., Chauhan, S. C., Chauhan, D. S., & Yallapu, M. M. (2024) · Nanotheranostics · doi:10.7150/ntno.91910 · Cited by 11
Suphanchaimat, R., Nittayasoot, N., Thammawijaya, P., Teekasap, P., & Ungchusak, K. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s318012 · Cited by 10
A meta-analysis of influenza vaccination following correspondence: Considerations for COVID-19
Murphy, R. P., Taaffe, C., Ahern, E., McMahon, G., & Muldoon, O. T. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.025 · Cited by 10
Ayurvedic Medicinal Plants Against COVID-19: An In Silico Analysis
Khuntia, B. K., Sharma, V., Qazi, S., Das, S., Sharma, S., Raza, K., & Sharma, G. (2021) · Natural Product Communications · doi:10.1177/1934578x211056753 · Cited by 10
Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19
Qi, H., Sun, Z., Yao, Y., Chen, L., & Su, X. (2022) · Vaccines · doi:10.3390/vaccines10030407 · Cited by 10
COVID‑19: Main findings after a year and half of unease and the proper scientific progress (Review)
Leretter, M. T., Vulcănescu, D. D., Horhat, F. G., Matichescu, A., Riviș, M., Rusu, L. C., Roi, A., Racea, R. C., Badea, I., Dehelean, C. A., et al. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11350 · Cited by 10
Lau, O., & Vadlamudi, N. K. (2021) · Value in Health · doi:10.1016/j.jval.2021.09.003 · Cited by 10
Patel, R. S., & Agrawal, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952229 · Cited by 10
Fontaine, E., & Saez, C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00234 · Cited by 9
Heftdal, L. D., Schultz, M., Lange, T., Knudsen, A. D., Fogh, K., Hasselbalch, R. B., Linander, C. B., Kallemose, T., Bundgaard, H., Grønbæk, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac012 · Cited by 9
Uprichard, S. L., O’Brien, A., Evdokimova, M., Rowe, C. L., Joyce, C., Hackbart, M., Cruz-Pulido, Y. E., Cohen, C. A., Rock, M. L., Dye, J. M., et al. (2022) · Viruses · doi:10.3390/v14020370 · Cited by 11
A Clinical Diagnostic Study: Fibulin-2 is a Novel Promising Biomarker for Predicting Infection
Li, S., Jiang, H., Xing, W., Wang, S., Zhang, Y., Li, Y., Mao, C., Zeng, D., Lan, P., Tang, D., et al. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00622-y · Cited by 9
COVID-19 Vaccination in Kidney Transplant Candidates and Recipients
Ponticelli, C., & Campise, M. (2022) · Vaccines · doi:10.3390/vaccines10111808 · Cited by 9
Bernal, E., García-Villalba, E., Pons, E., Vicente, M. R., Tomás, C., Minguela, A., Hernández, M. D., Puche, G., Carter, P., Martínez, M. M., et al. (2023) · Medicina Clínica · doi:10.1016/j.medcli.2022.12.018 · Cited by 8
Kola, S., Keely, A., & Walsh, J. C. (2023) · Psychology and Health · doi:10.1080/08870446.2023.2214569 · Cited by 9
Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity
Opdenakker, G., & Damme, J. V. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.01.004 · Cited by 9
Garrido, J. M., Martínez‐Rodríguez, D., Rodríguez‐Serrano, F., Pérez-Villares, J. M., Ferreiro-Marzal, A., Jiménez‐Quintana, M. D. M., & Villanueva, R. J. (2021) · Medicina Intensiva · doi:10.1016/j.medin.2021.02.014 · Cited by 9
Allam, A. A., & Sayed, A. A. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.07.006 · Cited by 9
Dong, C., Liang, Q., Ji, T., Gu, J., Feng, J., Shuai, M., Zhang, X., Zhao, R. Z., & Gu, Z. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111192 · Cited by 9
Wang, F., Wang, D., Wang, Y., Li, C., Zheng, Y., Guo, Z., Liu, P., Zhang, Y., Wang, W., Wang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.782198 · Cited by 9
Reactogenicity to COVID-19 vaccination in the United States of America
Sanyaolu, A. O., Marinkovic, A., Prakash, S., Desai, P., Haider, N., Abbasi, A. F., Mehraban, N., Jain, I., Ekeh, A., Shazley, O., et al. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.1.104 · Cited by 9
Parental coronavirus disease vaccine hesitancy for children in Bangladesh: a cross-sectional study
Ali, M., Ahmed, S. M. G., Bonna, A. S., Sarkar, A.-S., Islam, M. A., Urmi, T. A., & Proma, T. S. (2022) · F1000Research · doi:10.12688/f1000research.76181.2 · Cited by 9
First computational design using lambda-superstrings and in vivo validation of SARS-CoV-2 vaccine
Martínez, L., Malaina, I., Salcines-Cuevas, D., Terán-Navarro, H., Zeoli, A., Alonso, S., la Fuente, I. M. D., González-López, E., Ocejo-Vinyals, J. G., Gozalo-Margüello, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09615-w · Cited by 9
Hu, J., Zhao, M., Zhao, Y., Dong, W., Huang, X., & Zhang, S. (2022) · Obesity Science & Practice · doi:10.1002/osp4.626 · Cited by 8
COVID‐19 vaccination in children as a global dilemma through an ethical lens: A retrospective review
Assadi, M., Kiani, M., Gooshki, E. S., Aryanian, Z., Afshar, Z. M., & Hatami, P. (2022) · Health Science Reports · doi:10.1002/hsr2.976 · Cited by 8
Vaccination associated with gross domestic product and fewer deaths in countries and regions
Wang, L.-Y., Chien, T., Lin, J.-K., & Chou, W. (2022) · Medicine · doi:10.1097/md.0000000000028619 · Cited by 8
Koronavírus-világjárvány – a COVID–19-kaleidoszkóp ma (2022. május)
Falus, A. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32574 · Cited by 7
COVID-19 vaccination perception and uptake among cancer patients in Guangzhou, China
Fu, L., Wu, S., Wang, B., Zheng, W., Sun, Y., Tian, T., Zhang, X., Xu, L., Sun, Y., Zhan, J., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2102329 · Cited by 8
Serum peptidome profiles immune response of COVID-19 Vaccine administration
Zhang, W., Li, D., Xu, B., Xu, L., Lyu, Q., Liu, X., Li, Z., Zhang, J., Sun, W., Ma, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956369 · Cited by 8
Adam, A.-M., Vasilache, I.-A., Socolov, D. G., Stuparu-Crețu, M., Georgescu, C., Vicoveanu, P., Mihălceanu, E., Hărăbor, A., & Socolov, R. V. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206055 · Cited by 8
Liu, C., Zhang, J., Zeng, Y., Huang, C., Chen, F., Cao, Y., Wu, S., Wei, D., Lin, Z., Zhang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28280 · Cited by 6
Global landscape of COVID-19 research: a visualization analysis of randomized clinical trials
Zyoud, S. H. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01254-3 · Cited by 9
Statistical Observations on Vaccine Clinical Development for Pandemic Diseases
Patterson, S., Fu, B., Meng, Y., Bailleux, F., & Chen, J. (2021) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2021.1919197 · Cited by 8
Detection of SARS-CoV-2 through pool testing for COVID-19: an integrative review
Costa, M. S., Guimarães, N. S., de Andrade, A. B., Vaz-Tostes, L. P., Oliveira, R. B., Simões, M. D. S., Gelape, G. D. O., Alves, C. R. L., Machado, E. L., da Fonseca, F. G., et al. (2021) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0276-2021 · Cited by 9
Chen, L., Zhang, H., Li, M., Wu, B., Zhang, Z., & Gong, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1005321 · Cited by 8
Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity
Pacheco-García, U., & Serafín‐López, J. (2023) · Vaccines · doi:10.3390/vaccines11030655 · Cited by 8
Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trialsPreprint
Rose, S., Schmit, V. L., Darton, T. C., Eyal, N., Magalhães, M. D. A. F. M., Morrison, J., Peeler, M., Shah, S. K., & Marsh, A. A. (2021) · medRxiv · doi:10.1101/2021.03.14.21253548 · Cited by 8
Optimizing SARS-CoV-2 vaccination strategies in France: Results from a stochastic agent-based modelPreprint
Hoertel, N., Blachier, M., Limosin, F., Rico, M. S., Blanco, C., Olfson, M., Luchini, S., Schwarzinger, M., & Leleu, H. (2021) · medRxiv · doi:10.1101/2021.01.17.21249970 · Cited by 8
Yazdanparast, S., Bakhtiyaridovvombaygi, M., Mikanik, F., Ahmadi, R., Ghorbani, M., Mansoorian, M. R., Mansoorian, M., Chegni, H., Moshari, J., & Gharehbaghian, A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121907 · Cited by 7
COVID-19 Case Rates in the UK: Modelling Uncertainties as Lockdown Lifts
Brereton, C. F., & Pedercini, M. (2021) · Systems · doi:10.3390/systems9030060 · Cited by 7
Bloise, S., Marcellino, A., Frasacco, B., Gizzone, P., Ciolli, C. P., Martucci, V., Sanseviero, M., Giudice, E. D., Ventriglia, F., & Lubrano, R. (2022) · Vaccines · doi:10.3390/vaccines10081224 · Cited by 8
Kara, E., Tanır, F., Demırhındı, H., Mete, B., Kibar, F., Çeti̇ner, S., Candevir, A., & İnaltekin, A. (2022) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20229715 · Cited by 7
Milne, C., Wagner, R., Cano, F., Bruysters, M. W. P., Waeterloos, G., Pullirsch, D., Wierer, M., & Mallet, L. (2023) · npj Vaccines · doi:10.1038/s41541-023-00617-x · Cited by 7
Schulze, A., Brand, F., Leschzyk, D. K., Beuthner, M., Biegert, A., Bomnüter, U., Boy, B., Bucher, H.-J., Frau, R., Hubig, M. D., et al. (2023) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-023-03708-1 · Cited by 7
Dou, X., Peng, M., Jiang, R., Li, W., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1174406 · Cited by 7
Metadata
- Authors
- Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R. W., & Pollard, A. J.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Hodgson, Susanne H
- ORCID
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 21
- Issue
- 2
- Pages
- e26-e35
- ISSN
- 1473-3099 (ISSN-L)
- PMC
- PMC7837315
- OpenAlex
- W3088489318
- Cited by
- 633
- References
- 79
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 52 · 2023: 99 · 2022: 221 · 2021: 221
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- UK Research and Innovation (MC_PC_19055)
- Coalition for Epidemic Preparedness Innovations
- National Institute for Health Research
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- COVID-19 vaccines, SARS-CoV-2, vaccine efficacy, efficacy endpoints, vaccine development
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Clinical Trials as Topic, Humans, Research Design, Vaccination, Treatment Outcome, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
